enterobacteriaceae

Cefmenoxime hydrochloride (Cefmenoxime hemihydrochloride) is a cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date, no severe side effects have been noted.

Glycosyltransferase-IN-1 is a glycosyltransferase inhibitor with bacteriostatic activity, inhibiting MSSA, MRSA, Bacillus subtilis, and Enterobacteriaceae.

Plazomicin is a next-generation aminoglycoside that has been designed as an antibiotic to avoid resistance through aminoglycoside-modifying enzymes. Plazomicin shows high activity against the Enterobacteriaceae.

NOSO-95C is an antibacterial compound that bind to the bacterial ribosome and kill bacteria through inhibition of the translation. NOSO-95C showed promising in vitro and in vivo efficacy against Enterobacteriaceae.

Cefmenoxime sodium is the ssalt form of Cefmenoxime (free base), a cephalosporin antibiotic administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms. It is a potent inhibitor of Enterobacteriaceae, and is resistant to beta-lactamase-initiated hydrolysis. The drug has a high success rate against many types of infection.

SA09-Cu is a potent, noncompetitive inhibitor of NDM-1, with an IC50 of 9.6 nM. It inactivates NDM-1 by oxidizing the enzyme's Zn(II)-thiolate site and resists reduction by bacterial intracellular thiols. SA09-Cu effectively restores Meropenem efficacy against various clinical NDM-1-producing carbapenem-resistant Enterobacteriaceae (CRE) and hampers the progression of carbapenem resistance [1].

NOSO-502, exhibiting inhibitory activity against (Enterobacteriaceae), is a bacterial translation inhibitor that demonstrates good safety and antibacterial properties [1].

Cefteram (T-2525), an orally active ester of the cephalosporin class, is the free acid form of Cefteram pivoxil. This compound exhibits potent activity against enteropathogenic families Enterobacteriaceae and Vibrionaceae [1].

ANT431 is a novel metallo-β-lactamase inhibitor for the treatment of carbapenem-resistant enterobacteriaceae infections

LYS228 is a potent antibiotics against Carbapenem-Resistant Enterobacteriaceae (MIC90 = 2 uM/mL). LYS228 is potent in the presence of all classes of beta-lactamases.

Cefquinome is a cephem antibiotic that inhibits Enterobacteriaceae (family [1]).

BMS 180680 is a novel catechol-containing monolactam antibacterial active agent, which is the most effective compound against many species of Enterobacteriaceae.

Relebactam (MK-7655) is a diazabicyclooctane inhibitor with activity against a wide spectrum of β-lactamases.

CP 99433 is a new C-7 diazabicyclofluoroquinolone with a broad spectrum of activity that includes Enterobacteriaceae, Gram-positive cocci, and nonenteric Gram-negative bacilli.

WCK-4234 sodium (WCK 4234) is an inhibitor of β-lactamase can be used in studies targeting MDR infections. WCK-4234 sodium inhibits class A, C, and D β-lactamases and OXA carbapenemases.

Cefmenoxime is a cephalosporin antibiotic administered intravenously or intramuscularly. It is an effective inhibitor of Enterobacteriaceae and is resistant to beta-lactamase-initiated hydrolysis. It is active against most common gram-positive and gram-ne

Isepamicin (Sch 21420) is a potent aminoglycoside antibacterial compound with enhanced efficacy against strains harboring type I 6'-acetyltransferase. Its antibacterial spectrum encompasses Enterobacteriaceae and staphylococci, while exhibiting resistance against anaerobes, Neisseriaceae, and streptococci. Moreover, Isepamicin displays a robust concentration-dependent bactericidal effect, a prolonged post-antibiotic effect lasting several hours, and is capable of inducing adaptive resistance.